Menu Search
Equities

Trinity Biotech PLC

TRB:MUN

Trinity Biotech PLC

Actions
  • Price (EUR)2.12
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+5.47%
  • Beta--
Data delayed at least 15 minutes, as of Feb 22 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.

  • Revenue in USD (TTM)58.65m
  • Net income in USD-22.29m
  • Incorporated1992
  • Employees380.00
  • Location
    Trinity Biotech PLCIda Business ParkBray, Co Wicklow, IrelandBRAY 18IrelandIRL
  • Phone+353 12769800
  • Fax+353 12769888
  • Websitehttps://www.trinitybiotech.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		TRIB:NSQ since
announced		Transaction
value
Novus Diagnostics LtdDeal completed25 Oct 202425 Oct 2024Deal completed-10.93%--
Metabolomic Diagnostics LtdDeal completed24 Sep 202424 Sep 2024Deal completed30.40%--
Waveform Technologies Inc-Continuous Glucose Monitoring AssetsAnnounced31 Jan 202431 Jan 2024Announced-24.88%21.50m
Data delayed at least 15 minutes, as of Nov 11 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.